Phase II study of docetaxel monotherapy plus primary prophylaxis with pegfilgrastim for pre-treated locally advanced or metastatic non-small cell lung cancer.
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000016383
- Lead Sponsor
- Dept. Respiratory Medicine, Osaka Police Hopital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
(1) A history of docetaxel treatment (2)Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest X-ray film (3)Concurrent thoracic radiotherapy (4) A history of severe hypersensitivity against docetaxel or pegfilgrastim (5)Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer (6)Pleural effusion, ascites or peri-cardiac effusion requiring dranage. (7)Problematic complications (8) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (9) Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method